Home > Oncology > ASCO GU 2022 > Urothelial Carcinoma > No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma

No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma

Presented By
Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center, NY, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GU 2022
Trial
Phase 2, BAYOU
In the phase 2 BAYOU trial, first-line treatment with durvalumab plus olaparib did not prolong survival of patients with platinum-ineligible, unresectable, stage IV urothelial carcinoma compared with durvalumab plus placebo. The prognosis for patients with advanced urothelial carcinoma remains poor, particularly for those unable to tolerate platinum-based chemotherapy [1]. Mutations in homologous recombination repair (HRR) genes are common in urothelial carcinoma and render tumour cells sensitive to PARP inhibition [2]. PARP inhibition may enhance the anti-tumour response of immune checkpoint inhibitors. The randomised, phase 2 BAYOU study (NCT03459846) intended to evaluate durvalumab in combination with olaparib or placebo as a first-line treatment for platinum-ineligible patients with unresectable, stage IV urothelial carcinoma. BAYOU enrolled 154 patient...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on